Suad Hannawi - Search Results

Year	Number of Results
2006	1
2007	2
2009	1
2013	1
2014	1
2017	4
2018	3
2019	3
2020	14
2021	16
2022	14
2023	11
2024	6

1

Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.

Balgos A, Hannawi S, Chen WL, Abuquta A, Safeldin L, Hassan A, Alamadi A, Tirador L, Jaen AM, Villalobos RE, Mo C, Yue ZJ, Ma Y, Wang QS, Wen RD, Yao Z, Yu JP, Yao WR, Zhang JH, Hong KX, Liu Y, Li JX. Balgos A, et al. Among authors: hannawi s. Expert Rev Vaccines. 2024 Jan-Dec;23(1):419-431. doi: 10.1080/14760584.2024.2334423. Epub 2024 Apr 2. Expert Rev Vaccines. 2024. PMID: 38529685 Free article. Clinical Trial.

2

Is the patient-perceived impact of psoriatic arthritis a global concept? An international study in 13 Arab countries (TACTIC study).

Ziadé N, Abbas N, Hmamouchi I, El Kibbi L, Maroof A, Elzorkany B, Abdulateef N, Adnan A, Ihsan Awadh N, Gorial FI, Alchama N, Haouichat C, Alnaimat F, Hannawi S, Atawnah S, Halabi H, Al Mashaleh M, Aljazwi L, Abogamal A, Ayoub L, Bouajina E, Bahiri R, Saad S, Sabkar M, Aouad K, Gossec L. Ziadé N, et al. Among authors: hannawi s. Rheumatol Int. 2024 May;44(5):885-899. doi: 10.1007/s00296-024-05552-1. Epub 2024 Mar 18. Rheumatol Int. 2024. PMID: 38498150

3

The economic burden of systemic lupus erythematosus in United Arab Emirates.

Alansari A, Hannawi S, Aldhaheri A, Zamani N, Elsisi GH, Aldalal S, Naeem WA, Farghaly M. Alansari A, et al. Among authors: hannawi s. J Med Econ. 2024;27(sup1):35-45. doi: 10.1080/13696998.2024.2318996. Epub 2024 Mar 11. J Med Econ. 2024. PMID: 38468482 Free article.

4

Consensus-Based Overarching Principles and Recommendations on the Use of Biosimilars in the Treatment of Inflammatory Arthritis in the Gulf Region.

Alnaqbi KA, Al Adhoubi N, Aldallal S, Al Emadi S, Al-Herz A, El Shamy AM, Hannawi S, Omair MA, Saad SA, Kvien TK. Alnaqbi KA, et al. Among authors: hannawi s. BioDrugs. 2024 May;38(3):449-463. doi: 10.1007/s40259-023-00642-1. Epub 2024 Feb 25. BioDrugs. 2024. PMID: 38402494 Free PMC article.

5

Epidemiology, Management, and Outcome of Atypical Hemolytic Uremic Syndrome in an Omani Cohort.

Al Riyami D, Mohammed S, Al Salmi I, Metry A, Al Kalbani N, Almurshadi F, Al Rasbi S, Al Ismaili F, Hola A, Hannawi S. Al Riyami D, et al. Among authors: hannawi s. Oman Med J. 2023 Nov 30;38(6):e569. doi: 10.5001/omj.2023.117. eCollection 2023 Nov. Oman Med J. 2023. PMID: 38317858 Free PMC article.

6

COVID-19 Associated Acute Viral Myocarditis and Thyroid Gland Follicular Neoplasm in a Hemodialysis Patient.

Atris A, Al Salmi I, Hannawi S. Atris A, et al. Among authors: hannawi s. Oman Med J. 2023 Nov 30;38(6):e575. doi: 10.5001/omj.2023.75. eCollection 2023 Nov. Oman Med J. 2023. PMID: 38274949 Free PMC article.

7

Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine.

Zhao H, Zhang NN, Hannawi S, Zhu AR, Xiong XC, Huang YJ, Yu DD, Chen CJ, Dai J, Abuquta A, Ying B, Zhao JC, Qin CF. Zhao H, et al. Among authors: hannawi s. Cell Discov. 2024 Jan 9;10(1):7. doi: 10.1038/s41421-023-00609-0. Cell Discov. 2024. PMID: 38191591 Free PMC article. No abstract available.

8

Author Correction: Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men.

Hannawi S, Saf Eldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Xu S, Li J, Liu D, Baidoo AAH, Ibrahim D, Alhaj M, Chen Y, Zhou Q, Xie L. Hannawi S, et al. Nat Commun. 2024 Jan 8;15(1):369. doi: 10.1038/s41467-024-44729-x. Nat Commun. 2024. PMID: 38191554 Free PMC article. No abstract available.

9

Middle East Rheumatology Conference of the Gulf Cooperation Council association of Immunology and Rheumatology, December 9-11, 2022 Dubai, United Arab Emirates.

Zayat A, Omair M, Al-Nesf M, Lee M, Zaher ZA, Namas R, Al Mashhadani M, AlOkaily F, Hannawi S. Zayat A, et al. Among authors: hannawi s. Saudi Med J. 2023 Nov;44(11):1182-1213. Saudi Med J. 2023. PMID: 37926460 Free PMC article. No abstract available.

10

Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial.

Hannawi S, Yan L, Saifeldin L, Abuquta A, Alamadi A, Mahmoud SA, Hassan A, Zhang M, Gao C, Chen Y, Gai W, Xie L. Hannawi S, et al. EClinicalMedicine. 2023 Sep 8;64:102195. doi: 10.1016/j.eclinm.2023.102195. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37731938 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

71 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year